US 9,809,550 B2
Quinolyl hydrazones for the treatment of tuberculosis and related diseases
Ana Lucia Almeida Ferreira, Sáo Gregório CLD (PT); Ana Sofia Lopes, Loures (PT); Augusto Eugenio Pardal Filipe, Lisbon (PT); Pedro Filipe Eufrasio Pedroso, Lisbon (PT); Susana Marques De Almeida Pecorelli, Alcabideche (PT); and Carlos Caixado, Mafra (PT)
Assigned to TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A., Sintra (PT)
Appl. No. 14/443,787
Filed by TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A., Sintra (PT)
PCT Filed Nov. 20, 2013, PCT No. PCT/PT2013/000069
§ 371(c)(1), (2) Date May 19, 2015,
PCT Pub. No. WO2014/081325, PCT Pub. Date May 30, 2014.
Claims priority of application No. 106651 (PT), filed on Nov. 20, 2012.
Prior Publication US 2015/0299128 A1, Oct. 22, 2015
Int. Cl. C07D 215/38 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01)
CPC C07D 215/38 (2013.01) [A61K 31/47 (2013.01); A61K 31/4709 (2013.01)] 13 Claims
 
1. A method of treatment of infections caused by one or more of Mycobacterium tuberculosis Complex (MTbC), Mycobacterium leprae, and nontuberculous mycobacteria (NTM), comprising administering to a mammal an amount of a pharmaceutical composition comprising at least a compound of general Formula (I):

OG Complex Work Unit Drawing
(I)
wherein Q is

OG Complex Work Unit Drawing
and A is a 5-6 member substituted or unsubstituted aryl or heteroaryl ring selected from:

OG Complex Work Unit Drawing
whereinR1, R2 and R3 are each independently of one another, hydrogen, (C1-C4)alkyl, hydroxyl, halogen, methoxy or methoxy-acetic acid;andR4, R5, R6 and R7 are each independently of one another, hydrogen or (C1-C4)alkyl,or a pharmaceutically acceptable salt, ester, solvate, isomer or prodrug thereof.